Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    TopAbstracts in Cholesterol/Lipid Disorders 10/02/2008 - (DGNews)
    FDA Analysis Shows Statins Do Not Increase the Risk of ALS - (DGNews)
    TopAbstracts in Cholesterol/Lipid Disorders 09/18/2008 - (DGNews)
    Add-On Cholesterol Therapy Using Ezetimibe May Be More Effective Than Alternative Therapies Due to Pharmacological Synergy: Presented at ACCP - (DGDispatch)
    Statins Lower Risk of Recurrent Stroke in Both Elderly, Younger Patients - (DGNews)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
      Residual CV Risk and Future Treatment Strategies
      Vascular Protection and CB1 Blockade: Evolving Data
      Cardiometabolic Risk and Risk Management
      Understanding Metabolic Syndrome: Knowing the Risks
      Evidence-based Review of Lipid Treatment in 2008

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review
        Familial Hypercholesterolemia with Coarctation of Aorta
        Consideration of Polypharmacology in Regards to Effective Weight Reduction: A Patient on Diabetes Medication

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Adding Niacin to Lovastatin Therapy Might Improve Efficacy for Dyslipidemia: Presented at AAFP

        By Crystal Phend

        SAN FRANCISCO, CA -- October 5, 2005 -- Adding extended release niacin to lovastatin appears to improve lipoprotein control in patients with dyslipidemia compared to statin monotherapy, according to a study presented here on October 1st at the annual meeting of the American Academy of Family Physicians (AAFP).

        Statin therapy is a mainstay of treatment in patients with high levels of low-density lipoprotein (LDL) cholesterol and reduces the risk of cardiac events by about 30%. Niacin has been shown to be one of the most effective drugs for improving levels of high-density lipoprotein (HDL) cholesterol, or good cholesterol.

        "Combining the best LDL lowering and best HDL raising drugs makes sense," said lead author Jason Logan, MD, Family Physician, In His Image Family Practice Residency, Tulsa, Oklahoma, United States.

        In the prospective, open label, single-intervention trial, the researchers compared lipid profiles of 67 participants receiving combination treatment against baseline measurements and against results from a similarly designed study using atorvastatin (Calcium Antagonist Reinfarction Italian Study).

        The 67 patients received 500 mg of extended-release niacin and 20 mg of lovastatin to start and were titrated up to 1000 mg of niacin. All participants were receiving standard care but were not meeting LDL goals as set by the National Heart, Lung and Blood Institute's cholesterol guidelines.

        Of the 61 patients who completed the study, 20 were on statin monotherapy and 41 were on therapeutic lifestyle modification alone at baseline.

        In the group previously on statin alone, 75% of patients achieved LDL cholesterol goals on combination therapy. LDL decreased by 33.4% on average and HDL increased by 18.9%. Triglycerides decreased by 30.2%.

        Those who had not taken statins prior to the study had an even higher risk reduction (62.9% versus 59.7%). A clinically significant 90.2% of patients met the LDL goal with an average decrease of 43.8%. Triglycerides improved by 41.8% and HDL increased by 15.4%.

        Comparing this to the atorvastatin study results, the coronary artery disease risk reduction with combination therapy was superior to atorvastatin alone (65.7% compared to 38.8%).

        One patient withdrew from the study due to flushing related to niacin therapy; 16% of patients reported flushing, which improved over time, Dr. Logan said.

        "Combination therapy with niacin extended-release and lovastatin is underused," he added, "but may be the most effective treatment for substantially correcting both of these lipoprotein abnormalities and drastically reducing coronary artery disease risk."


        [Presentation title: Extended-Release Niacin/Lovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting ("EXTEND" Study). Family Medicine Research Presentations]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send